Nazwa | INN | Postać | Dawka | Opakowanie | Cena (PLN) | Status |
---|---|---|---|---|---|---|
COVID-19 mRNA vaccine (nucleoside-modified) | inj. [konc. do sporz. dyspersji] | 30 µg/dawkę | 195 fiol. (975 dawek) | 100% X |
Rx
|
|
COVID-19 mRNA vaccine (nucleoside-modified) | inj. [konc. do sporz. dyspersji] | 30 µg/dawkę | 15 fiol. (75 dawek) | 100% X |
Rx
|
|
COVID-19 mRNA vaccine (nucleoside-modified) | inj. [konc. do sporz. dyspersji] | 30 µg/dawkę | 5 fiol. 30 dawek (6 dawek/fiol.) | 100% X |
Rx
|
|
COVID-19 mRNA vaccine (nucleoside-modified) | inj. [konc. do sporz. dyspersji] | 10 µg/dawkę | 10 fiol. (100 dawek) | 100% X |
Rx
|
|
COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspersja] | (15/15 µg)/dawkę | 10 fiol. 2,25 ml | 100% X |
Rx
|
|
COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspersja] | (15/15 µg)/dawkę | 195 fiol. 2,25 ml | 100% X |
Rx
|
|
COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspersja] | (15/15 µg)/dawkę | 10 fiol. 2,25 ml | 100% X |
Rx
|
|
COVID-19 mRNA vaccine (nucleoside-modified) | inj. [dyspersja] | (15/15 µg)/dawkę | 195 fiol. 2,25 ml | 100% X |
Rx
|